University of Thessaly (UTH)
Yγρή βιοψία σε ασθενείς με Μη-Μικροκυτταρικό Καρκίνο Πνεύμονα και μετάλλαξη του Υποδοχέα του Επιδερμικού Αυξητικού Παράγοντα, οι οποίοι λαμβάνουν θεραπεία με osimertinib
Abstract
dc:descriptionOsimertinib is a non-reversible epidermal growth factor receptor (EGFR) inhibitor, selective for EGFR activating mutations and the T790M resistance mutation. Liquid biopsy, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), may confer prognostic and predictive information during treatment with tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) and EGFR mutation. The aim of this dissertation was to evaluate the clinical relevance of liquid biopsy in patients with EGFR-mutant NSCLC, who received osimertinib after disease progression on a first- or second-generation EGFR tyrosine kinase inhibitor (TKI). Forty-seven patients EGFR-mutant NSCLC patients who had progressed on prior first- or second-generation EGFR TKIs were enrolled in the study and treated with osimertinib 80 mgr daily, irrespective of the presence of the T790M mutation in the primary tumor or the plasma. Peripheral blood was collected at baseline (n = 47), after one month of treatment1 (n = 47), and at the end of treatment (EOT; n = 39) and ctDNA was isolated and analyzed. CTCs were evaluated in 32 patients at the same time points (n = 32, n = 27, and n = 21, respectively) and phenotypic characterization was performed using triple immunofluorescence staining (cytokeratin, CK/ vimentin, VIM/ CD45). Osimertinib resulted in an objective response rate of 34% and a disease control rate (response and disease stabilization) of 76.6%. The median progression-free (PFS) and overall survival (OS) values were 7.5 and 15.1 months, respectively. ctDNA was detected in 61.7%, 27.7%, and 61.5% of patients at baseline, after one month of treatment and EOT, respectively. CTCs were detected in 68.8%, 48.1%, and 61.9% of patients at the three time points, respectively. CTCs expressing both epithelial and mesenchymal markers (CK+/VIM+/CD45-) were detected in 56.3%, 29.6% and 38% of patients at baseline, after one month of treatment and at EOT, respectively. The detection of ctDNA at baseline and post-Cycle 1 was associated with shorter PFS and OS, whereas the ctDNA clearance post-Cycle 1 resulted in a significantly longer PFS and OS. Positive liquid biopsy (ctDNA and/or CTCs) at baseline was associated with shorter PFS. Treatment with osimertinib resulted in early decrease in both CTCs and ctDNA. ctDNA at baseline and after one month of treatment with osimertinib, as well as a positive liquid biopsy at baseline, were correlated with clinical outcomes.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kontopodis, Emmanouil
- Κοντοπόδης, Εμμανουήλ
Subjects
dc:subject × 14- Μη-μικροκυτταρικός καρκίνος του πνεύμονος
- Osimertinib
- Κυκλοφορούν DNA
- Καρκινικά κύτταρα, Κυκλοφορούντα
- Non-small cell lung cancer
- EGFR mutations
- Circulating tumor DNA (ctDNA)
- Circulating tumor cells
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Clinical Medicine
- Medical and Health Sciences
- Oncology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62878